Table 2.
Significant results relating key independent variables to TB outcomes
| Outcome variable | Significant key independent variable | Effect on outcome variable after a 1% increase of the key independent variable | 95% CI | P-value | Fit |
|---|---|---|---|---|---|
| TB Incidence per 100,000 | % of NTP budget for MDR-TB | Increase of 1 case per 100,000 | 0.99–1.00 case per 100,000 | 0.032 | AIC−27.0 |
| TB Case detection rate (%) | % of NTP budget for ACSM/CTBC | 0.27% increase | 0.07%–0.47% | 0.02 | AIC 166.6 |
| Smear Positive TB deaths per smear positive TB cases | % of NTP budget for First-Line Drugs | 0.1% decrease | 0.02%–0.2% | 0.02 | QIC 2.4112 |
| % of NTP budget for Management and Administration | 0.13% decrease | 0.09%–0.17% | <0.0001 | ||
| % of NTP budget for MDR-TB | 0.05% decrease | 0.01%–0.09% | 0.007 | ||
| % of NTP budget for DOT | 0.11% increase | 0.04%–0.17% | 0.0002 | ||
| NTP budget/GDP (std dev = 0.0013) | 0.9% increase | 0.55%–1.2% | <0.0001 | ||
| Notification per TB incidence | % of NTP budget for Laboratory supplies and equipment | 0.18% increase | 0.012%–0.34% | 0.05 | AIC−15.7 |
| Drug susceptibility testing among TB patients per TB incidence | % of the population covered by DOT | 114% increase | 95%–130% | 0.01 | AIC 75.3 |
| HIV testing among TB patients per TB incidence | % of NTP budget for TB-HIV | 1.13% increase | 0.6%–1.6% | <0.0001 | QIC 44.0707 |
| NTP budget/GDP (std dev = 0.0013) | 7% decrease | 1.7%–12% | 0.009 |
AIC: Akaike information criteria; QIC: Quasilikelihood under the Independence model Criterion